RecruitingNCT00001595
Endocrine
Acromegaly
Also known as Growth hormone excess, GH-secreting pituitary adenoma, somatotropinoma, IGF-1 excess
Acromegaly is caused by chronic hypersecretion of growth hormone, almost always from a GH-secreting pituitary adenoma (somatotropinoma), resulting in elevated IGF-1 levels and progressive somatic overgrowth of acral and soft tissues, organo
ORPHA:963 ↗Prevalence 40–70 per millionOnset Adults, typically in the fourth to sixth decadeSporadic (vast majority); rarely MEN1 or FIPA-associated
12
studies recruiting now
as of 7 Sept 2026
206
studies registered in total
as of 7 Sept 2026
21
countries with a recruiting site
as of 7 Sept 2026
11 Jun 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT06930625
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
RecruitingPhase 2NCT07641179
A Study to Evaluate MAR002 for Acromegaly
RecruitingNCT07583563
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
RecruitingNCT00461188
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 12 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Acromegaly study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: Acromegaly Database Consortium (AcroDB) · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Acromegaly
Acromegaly is caused by chronic hypersecretion of growth hormone, almost always from a GH-secreting pituitary adenoma (somatotropinoma), resulting in elevated IGF-1 levels and progressive somatic overgrowth of acral and soft tissues, organomegaly, and metabolic disturbances. The diagnosis is typically delayed by seven to ten years due to the insidious onset of physical changes, during which time cumulative exposure to excess GH and IGF-1 drives substantial cardiovascular, respiratory, and metabolic comorbidities that are major determinants of mortality. Treatment aims to normalise GH and IGF-1 levels through surgery, somatostatin receptor ligands, dopamine agonists, GH receptor antagonism, or radiotherapy, with disease control defined as IGF-1 within the age-normalised reference range.
Common clinical features
Enlargement of hands and feet with ring and shoe size increaseCoarsening of facial features with frontal bossing and prognathismMacroglossia and dental spacingHyperhidrosis and oily skinArthropathy and joint painSleep apnoea (obstructive and central)Hypertension, cardiomegaly, and left ventricular hypertrophyHeadache and visual field defects from local tumour mass effect
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
7 approved treatments and 10 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Pasireotide Pamoate (Signifor lar)Approved: Lanreotide Acetate (Somatuline depot)Approved: Pasireotide (Signifor)Approved: Pegvisomant (Somavert)Approved: Bromocriptine Mesylate (Bromocriptine mesylate)Approved: Octreotide Acetate (Bynfezia pen)Approved: Octreotide
Phase 3Lanreotide (Somatuline autogel)
Phase 3Paltusotine
Phase 3Octreotide Hydrochloride
Phase 2Veldoreotide
Phase 2Clomiphene Citrate (Clomid)
Phase 2Onzigolide
Phase 2Edotreotide
Phase 2Cimderlirsen Sodium
+ 2 more in development
Before you apply
Things trial teams commonly ask about for Acromegaly. Not eligibility rules; those are set by each study.
- Active acromegaly confirmed by failure to suppress GH below 1 ng/mL during oral glucose tolerance test plus elevated age-adjusted IGF-1 is required for most interventional trials; bring recent pituitary MRI and hormone results.
- Prior treatment history (surgery, radiotherapy, and pharmacological agents including somatostatin analogues, pegvisomant, and cabergoline) affects eligibility for trials of novel agents; doses and duration should be well documented.
- Comorbidity burden (sleep apnoea severity, cardiac function, glucose metabolism) is assessed at screening; a sleep study, echocardiography, and HbA1c within six months of enrolment are commonly required.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).